Study Summary
This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients developed CD19-negative disease after CD19 CART immunotherapy. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Want to learn more about this trial?
Request More InfoInterventions
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPRBIOLOGICAL
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Zhujiang Hospital of Southern Medical University | Guangzhou | Guangdong | China |
| Shenzhen Geno-immune Medical Institute | Shenzhen | Guangdong | China |
| Zhongxi Children Hospital | Shijiazhuang | Hebei | China |